Donation after cardiac death – pre-treatment of the donor with erythropoietin (experimental study)

Authors

  • Manuel Fraga Martins Maio
  • Nuno Filipe Leitão Figueiredo Interno do Internato Complementar de Cirurgia Geral, Coordenador de Transplantes do Gabinete de Coordenação de Colheitas e Transplantação do Hospital de Santa Maria – Clínica Universitária de Cirurgia I – Hospital Santa Maria; Faculdade de Medi- cina, Universidade de Lisboa
  • Isa Maria Dias Fernandes dos Santos Interna do Internato Complementar de Cirurgia Geral – Clínica Universitária de Cirurgia I – Hospital Santa Maria; Faculdade de Medicina, Universidade de Lisboa
  • Hélder Mota Filipe Professor Associado de Farmacologia da Universidade de Lisboa – Unidade de Farmacologia e Farmacotoxicologia, Faculdade de Farmácia, Universidade de Lisboa
  • Afonso Fernandes Director de Serviço, Chefe de Serviço, Professor Agregado da Faculdade de Medicina da Universidade de Lisboa – Serviço de Ana- tomia Patológica – Hospital de Santa Maria; Faculdade de Medicina, Universidade de Lisboa
  • Paulo Sérgio Matos da Costa Director de Serviço, Chefe de Serviço, Professor Agregado da Faculdade de Medicina da Universidade de Lisboa, Fellow of the Royal College of Surgeons, Fellow of the American College of Surgeons – Clínica Universitária de Cirurgia I – Hospital Santa Maria; Faculdade de Medicina, Universidade de Lisboa

Abstract

Introduction – Donation after cardiac death offers an interesting alternative to reduce organ shortage. Nevertheless these organs are subjected to a greater ischemia-reperfusion injury which impairs immediate and long term transplant results. We have recently demonstrated an important renal protective effect of erythropoietin (EPO), in a rat ischemia-reperfusion model. 

Material and Methods – In a pig model we simulated the conditions of donation after cardiac death (DCD) followed by kidney transplant. Cardiac arrest was induced and the kidneys extracted after 30 minutes of warm ischemia, then preserved with CelsiorTM at 4oC. Twenty four hours later they were transplanted using a heterotopic technique. In the pre-treated group, 1000 units of EPO/kg were administered 30 minutes before cardiac death. At the end of the experiment, blood, urine and renal tissue samples were collected for analysis. Graph Pad Prism Statistical Package (version 3.0) was used for statistical analysis and p<0,05 considered statistically significant.

Results – Transplantation of DCD kidneys resulted in elevation of serum levels of creatinine, N-acetil-β-D- glucosaminidase (NAG), glutathione-S-transferase (GST), AST, LDH, ALT, sodium excretion fraction, interleukin 1 and 6, malondialdehyde (MDA) and myeloperoxidase activity (MPO). There was also a significant reduction in urinary flow and creatinine clearance (p<0,05). Histological evaluation demonstrated architectural damage and necrosis. EPO administration 30 minutes before ischemia reduced significantly the biochemical and histological changes from glomerular dysfunction and tubular lesion. It also diminished systemic injury, inflammatory response and oxidative stress (p<0,05).

Conclusion: Our study demonstrated that donor pre-treatment with a single dose of EPO induces a considerable reduction in kidney dysfunction and systemic injury associated with renal transplantation from DCD donors.

KEYWORDS: Donation after cardiac death, Erythropoietin, Renal Transplant, Ischemia-Reperfusion Injury 


Downloads

Download data is not yet available.

Author Biography

Manuel Fraga Martins Maio

Assistente Hospitalar de Cirurgia Geral, Director-Adjunto do Gabinete de Coordenação de Colheitas e Transplantação do Hos- pital de Santa Maria, “Certified European Transplant Coordinator”, Conselheiro da European Transplant Coordinators Organi- zation – Clínica Universitária de Cirurgia I – Hospital Santa Maria; Faculdade de Medicina, Universidade de Lisboa

Published

2007-12-28

Issue

Section

Original Papers